International Journal of Radiation Biology · 2018 · 25 citations · 41 references
MedicineOncologyPharmacologyMetastasisMolecular OncologyTumor ProgressionBone MetastasisCancer Stem CellsMalignant NeoplasmsMetastatic Bone DiseaseProstate CancerRadiation TherapyAndrogen Deprivation Therapy ResistanceCancer Stem Cell RadioresistanceCastration-resistant Prostate Cancer TherapyMetastatic Castration-resistant Prostate CancerProstate Cancer Hormonal TherapyRadium TherapyReversal Of Drug ResistanceTherapeutic Resistance Mechanisms
In the history of prostate cancer, some of the patients progressed to castration-resistant prostate cancer (CRPC) stage and, although new drugs and treatment protocols have been introduced, CRPC presents poor prognosis. This review is focused on biological mechanisms, underlying CRPC described in scientific literature in order to explain the reversion of resistance to castration. We present the case of a 73-year-old man, affected by bone metastatic CRPC, early treated with Radium-223 with a complete response. After 15 months from Radium-223 treatment, prostate-specific antigen increased with radiological progression. Androgen deprivation therapy was again performed and was effective, despite previous CRPC condition and no known mechanisms that may explain the reversion of this condition. Therefore, to our knowledge, he is the unique described case of the reversion of resistance to castration. Nevertheless, promising aspects may be lack of intrametastatic production of androgen or the suppression of bypass androgen receptor signaling pathways. Furthermore, the cytotoxic action of Radium-223 on cancer stem cell (CSC), due to surrounding clones with high-bone turnover, or the immune response that underlying the abscopal effect, may also modulate the reversion of CRPC after Radium-223. If confirmed by multicenter trials, the reversion of CRPC may impact on the management of prostate cancer.
41
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao, Qiulian Wu, Roger E. McLendon et al. · Nature · 2006 · 6.4K citations
Medicine, Cancer Biology, Oncology +16
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad et al. · New England Journal of Medicine · 2012 · 4.6K citations · Full text
Medicine, Oncology, Pharmacology +14
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor, Nikolaus Schultz, Haley Hieronymus et al. · Cancer Cell · 2010 · 3.8K citations · Full text
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan R. Robinson, Eliezer M. Van Allen, Yi-Mi Wu et al. · Cell · 2015 · 3.6K citations · Full text